The hallmarks of cancer immune evasion
- PMID: 39393356
- DOI: 10.1016/j.ccell.2024.09.010
The hallmarks of cancer immune evasion
Abstract
According to the widely accepted "three Es" model, the host immune system eliminates malignant cell precursors and contains microscopic neoplasms in a dynamic equilibrium, preventing cancer outgrowth until neoplastic cells acquire genetic or epigenetic alterations that enable immune escape. This immunoevasive phenotype originates from various mechanisms that can be classified under a novel "three Cs" conceptual framework: (1) camouflage, which hides cancer cells from immune recognition, (2) coercion, which directly or indirectly interferes with immune effector cells, and (3) cytoprotection, which shields malignant cells from immune cytotoxicity. Blocking the ability of neoplastic cells to evade the host immune system is crucial for increasing the efficacy of modern immunotherapy and conventional therapeutic strategies that ultimately activate anticancer immunosurveillance. Here, we review key hallmarks of cancer immune evasion under the "three Cs" framework and discuss promising strategies targeting such immunoevasive mechanisms.
Keywords: T cell exhaustion; T(REG) cells; antigen presentation; cytotoxic T lymphocytes; dendritic cells; exclusion; immune checkpoint inhibitors; immunogenic cell death; tumor-associated macrophages; type I interferon.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests T.A.C. is a co-founder of Gritstone Oncology and holds equity in Gritstone Oncology and An2H, is/has been holding research contracts with Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai, has served as an advisor for Bristol-Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca, and An2H, and is an inventor on intellectual property and a patent held by MSKCC on using tumor mutation burden to predict immunotherapy response, which has been licensed to PGDx. L.G. is/has been holding research contracts with Lytix Biopharma, Promontory, and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, AbbVie, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical